The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Zhuang, Hong Qing ^a,b   Wang, Jun ^a,b   Yuan, Zhi Yong ^a,b   Zhao, Lu Jun ^a,b   Wang, Ping ^a,b   Wang, Chang Li ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Lung Cancer Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTINEOPLASTIC AGENT; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; IRRADIATION; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RECEPTOR BLOCKING; UPREGULATION; WESTERN BLOTTING; X RAY; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; UP-REGULATION; X-RAYS;

EID: 70349086575     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-123     Document Type: Article

References (41)

1. Growth inhibition of human tumor cells in athymicmice by anti-epidermal growth factor receptor monoclonal antibodies. H Masui T Kawamoto JD Sato, Cancer Res 1984 44 1002 1007 6318979
2. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. P Yaish A Gazit C Gilon, Science 1988 242 933 935 10.1126/science.3263702 3263702
3. The discovery of receptor tyrosine kinases: targets for cancer therapy. A Gschwind OM Fischer A Ullrich, Nat Rev Cancer 2004 4 361 370 10.1038/nrc1360 15122207 (Pubitemid 38579482)
4. Epidermal growth factor receptor pathway inhibitors. B Jose, Update on cancer therapeutics 2006 1 299 310 10.1016/j.uct.2006.08.002 (Pubitemid 44375078)
5. EGFR Antagonists in Cancer Treatment. C Fortunato T Giampaolo, N Engl J Med 2008 358 1160 1174 10.1056/NEJMra0707704 18337605
6. Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor. C Fortunato T Giampaolo, Clinical Cancer Res 2001 7 2958 2970
7. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. ZP Zhu, Acta Pharmacol Sin 2007 28 1476 1493 10.1111/j.1745-7254.2007.00681.x 17723181
8. Epidermal growth factor receptor inhibition strategies in oncology. PM Harari, Endocr Relat Cancer 2004 11 689 708 10.1677/erc.1.00600 15613446
9. EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors Similarities and differences. D Olivier Alexandre M Gerard, Crit Rev Oncol Hemato 2007 62 53 61 10.1016/j.critrevonc.2006.12.008 (Pubitemid 46330798)
10. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. MG Kris RB Natale RS Herbst, JAMA 2003 290 2149 2158 10.1001/jama.290.16.2149 14570950
11. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial)[corrected]. M Fukuoka S Yano G Giaccone, J Clin Oncol 2003 21 2237 2246 10.1200/JCO.2003.10.038 12748244
12. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. JA Bonner PM Harari J Giralt, N Engl J Med 2006 354 567 578 10.1056/NEJMoa053422 16467544
13. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. D Cunningham Y Humblet S Siena, N Engl J Med 2004 351 337 345 10.1056/NEJMoa033025 15269313
14. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. DA Haas-Kogan MD Prados T Tihan, J Natl Cancer Inst 2005 97 880 887 15956649
15. Molecular determinants of the response of glioblastomas to EGFR kinaseinhibitors. IK Mellinghoff MY Wang I Vivanco, N Engl J Med 2005 353 2012 2024 10.1056/NEJMoa051918 16282176
16. Somatic mutations of EGFR in colorectal cancers and Glioblastomas. TD Barber B Vogelstein KW Kinzler, N Engl J Med 2004 351 2270 2883 10.1056/NEJM200412303512724 (Pubitemid 40051921)
17. EGFR tyrosine kinase domain mutations in human gliomas. Y Marie AF Carpentier AM Omuro, Neurology 2005 64 1444 1445 15851741
18. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. B Roberto S Incheol Christoph A Ritter, Oncogene 2003 22 2812 2822 10.1038/sj.onc.1206388 12743604
19. Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. K Ingo Mellinghoff Y Maria P Wang, N Engl J Med 2006 354 884 897
20. PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme. Justin S Smith T Issei M Sandra, J Natl Cancer Inst 2001 93 1246 1256 10.1093/jnci/93.16.1246 11504770
21. Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Y Harima S Sawada K Nagata, Int J Oncol 2001 18 493 497 11179477
22. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. H Endoh Y Yatabe T Kosaka, J Thorac Oncol 2006 1 629 634 17409929
23. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Baselga CL Arteaga, J Clin Oncol 2005 23 2445 2259 10.1200/JCO.2005.11.890 15753456
24. olecular Cloning. Sambrook J David Russell, America: CSHL Press Third 2000 1235 1262
25. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Z Fan H Masui I Altas, Cancer Res 1993 53 4322 4328 8364927
26. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Z Fan Y Lu X Wu, J Biol Chem 1994 269 27595 27602 7961676
27. Mechanisms of Enhanced Radiation Response following EpidermalGrowth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). C Prakash H Shyhmin V Geetha, Cancer Res 2005 65 3328 3335 15833866
28. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt pathway. HC Byeong GK Chang L Yoongho, Cancer Letters 2008 259 111 118 10.1016/j.canlet.2007.10.003 18006147
29. The phosphatidylinositol 3-kinase AKT pathway in human cancer. I Ivanco CL Sawyers, Nat Rev Cancer 2002 2 489 501 10.1038/nrc839 12094235
30. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. W Liu CD James L Frederick, Cancer Res 1997 57 5254 5257 9393744
31. Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. T Yakut A Gutenberg A Bekar, Oncol Rep 2007 17 1037 1043 17390041
32. PAkt, cyclin D1 and p27/Kip.1 in glioblastomas with and without EGFR amplification and PTEN mutation. V Fiano C Ghimenti S Imarisio, Anticancer Res 2004 24 2643 2647 15517868
33. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium. R Rotterud SD Fossa JM Nesland, Histol Histopathol 2007 22 349 363 17290345
34. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. IF Pollack RL Hamilton CD James, J Neurosurg 2006 105 418 424 10.3171/jns.2006.105.3.418 17328268
35. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. QB She DB Solit Q Ye, Cancer Cell 2005 8 287 297 10.1016/j.ccr.2005.09.006 16226704
36. Effects of cotransfection of antisense-EGFR and wild-type PTEN cDNA on human glioblastoma cells. XX Tian YG Zhang J Du, Neuropathology 2006 26 178 187 10.1111/j.1440-1789.2006.00679.x 16771172
37. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. JA Kraus J Felsberg JC Tonn, Neuropathol Appl Neurobiol 2002 28 325 333 10.1046/j.1365-2990.2002.00413.x 12175345
38. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. S Anai S Goodison K Shiverick, Hum Gene Ther 2006 17 975 984 10.1089/hum.2006.17.975 16984224
39. PTEN Gene Targeting Reveals a adiation- Induced Size Checkpoint in Human Cancer Cells. C Lee JS Kim T Waldman, Cancer Res 2004 64 6906 6914 10.1158/0008-5472.CAN-04-1767 15466180
40. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signaling. V Thierry DA Eileen B Veronique, Nat Cell Biol 2001 3 1124 1129 10.1038/ncb1201-1124 11781575
41. Study on construction of pegfr-hPTEN expression vector induced by irradiation and anti-tumor effect in vitro. M Tian GH Jin CH Piao, Chin J Radiol Prot 2003 23 423 426 10.1088/0952-4746/23/4/005 (Pubitemid 38145610)